Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
DUBLIN April 24, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago . Presentations include data from trials of zanidatamab, Zepzelca ® (lurbinectedin), and Rylaze ® (asparaginase erwinia chrysanthemi (recombinant)-rywn). A poster featuring the study design for the JZP898 Phase 1 trial in progress will also be presented. Updated data with longer follow-up, including overall survival findings, will be presented from the Phase 2b HERIZON-BTC-01 trial of zanidatamab, a HER2-targeted bispecific, biparatopic antibody, in previously treated HER2-positive biliary tract cancer (BTC). Data from the HERIZON-BTC-01 trial were the backbone of the recently completed Biologics License Application (BLA) submission for previously treated HER2-positive metastatic BTC. "We are excited to p
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.MarketBeat
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Barclays PLC from $230.00 to $200.00. They now have an "overweight" rating on the stock.MarketBeat
- Jazz Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $222.00 price target on the stock.MarketBeat
JAZZ
Earnings
- 5/1/24 - Miss
JAZZ
Sec Filings
- 5/3/24 - Form 144
- 5/2/24 - Form 10-Q
- 5/1/24 - Form 8-K
- JAZZ's page on the SEC website